Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.

Age does not affect treatments, outcomes in hepatocellular carcinoma

19 Sep 2017

Age appears to not significantly impact treatments and outcomes for hepatocellular carcinoma (HCC), a new study reveals. Survival is comparable between older and younger patients, and equally active treatments should be administered to both age groups.

The study included 1,530 adult patients diagnosed with HCC, of which 20.8 percent (n=318) were older than 65 years while the remaining 79.2 percent (n=1,212) were younger. Cigarette and alcohol use and liver cirrhosis were significantly more common in younger patients (p<0.05 for all).

Prior to propensity score matching, there was no significant difference in 30-day mortality between the two groups (p=0.884). In contrast, the 90-day mortality was significantly higher in older than in younger patients (13.2 vs 9.4 percent; p=0.048). The global median 1-, 3- and 5-year survival rates were also worse in older patients.

After propensity score matching for preoperative status, liver function, tumour size and vascular invasion, among others, the statistically significant difference in 90-day mortality was attenuated.

In spite of this, older patients were given curative treatments, such as surgical resection (28.9 vs 24.6 percent) and liver transplant (3.3 vs 0 percent), significantly less than younger patients (p<0.001).

“These findings implied that even with similar host factors and tumour burden, older patients tended to be less aggressively treated than younger patients, which might account for the diminished long-term outcome of elderly patients,” said researchers.

Subsequent multivariable analysis showed that age (hazard ratio [HR], 1.1; 95 percent CI, 0.9 to 1.3; p=0.281) did not significantly affect survival. On the other hand, curative treatments (HR, 0.5; 0.4 to 0.6; p<0.001), locoregional therapies (HR, 0.8; 0.7 to 0.9; p<0.001) and the Eastern Cooperative Oncology Group scores (HR, 1.4; 1.2 to 1.6; p<0.001) were all significantly associated with survival.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.